Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
1999 1
2000 3
2001 4
2002 8
2003 4
2004 7
2005 7
2006 7
2007 4
2008 5
2009 5
2010 4
2011 6
2012 6
2013 14
2014 19
2015 8
2016 15
2017 11
2018 8
2019 11
2020 13
2021 23
2022 12
2023 14
2024 10
2025 14
2026 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

212 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean p vassilakopoulos tp[au] (65 results)?
Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed/refractory classical Hodgkin lymphoma.
Armand P, Zinzani PL, Lee HJ, Johnson NA, Brice P, Radford J, Ribrag V, Molin D, Vassilakopoulos TP, Tomita A, von Tresckow B, Shipp MA, Herrera AF, Lin J, Kim E, Chakraborty S, Marinello P, Moskowitz CH. Armand P, et al. Among authors: vassilakopoulos tp. Blood. 2023 Sep 7;142(10):878-886. doi: 10.1182/blood.2022019386. Blood. 2023. PMID: 37319435 Free PMC article.
Thrombocytosis.
Liaskas A, Vassilakopoulos TP. Liaskas A, et al. Among authors: vassilakopoulos tp. Blood. 2024 Apr 25;143(17):1782. doi: 10.1182/blood.2023023702. Blood. 2024. PMID: 38662384 Free article. No abstract available.
Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial.
Falchi L, Nijland M, Huang H, Linton KM, Seymour JF, Tao R, Kwiatek M, Costa A, Vassilakopoulos TP, Greil R, Jiménez-Ubieto A, Gangatharan SA, Benjamini O, Thieblemont C, Tucci A, Elinder-Camburn A, Illes A, Novak J, Pavlovsky MA, McDonald A, Yoon DH, Maruyama D, Sunkersett G, Mei JP, Mukherjee N, Zhu F, Alshreef A, Favaro E, Morschhauser F; EPCORE FL-1 Investigators. Falchi L, et al. Among authors: vassilakopoulos tp. Lancet. 2026 Jan 10;407(10524):161-173. doi: 10.1016/S0140-6736(25)02360-8. Epub 2025 Dec 7. Lancet. 2026. PMID: 41371238 Free article. Clinical Trial.
Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial.
Kalakonda N, Maerevoet M, Cavallo F, Follows G, Goy A, Vermaat JSP, Casasnovas O, Hamad N, Zijlstra JM, Bakhshi S, Bouabdallah R, Choquet S, Gurion R, Hill B, Jaeger U, Sancho JM, Schuster M, Thieblemont C, De la Cruz F, Egyed M, Mishra S, Offner F, Vassilakopoulos TP, Warzocha K, McCarthy D, Ma X, Corona K, Saint-Martin JR, Chang H, Landesman Y, Joshi A, Wang H, Shah J, Shacham S, Kauffman M, Van Den Neste E, Canales MA. Kalakonda N, et al. Among authors: vassilakopoulos tp. Lancet Haematol. 2020 Jul;7(7):e511-e522. doi: 10.1016/S2352-3026(20)30120-4. Lancet Haematol. 2020. PMID: 32589977 Free article. Clinical Trial.
Hodgkin lymphoma: Introduction.
Engert A, Vassilakopoulos TP. Engert A, et al. Among authors: vassilakopoulos tp. Semin Hematol. 2016 Jul;53(3):137-8. doi: 10.1053/j.seminhematol.2016.05.001. Epub 2016 May 12. Semin Hematol. 2016. PMID: 27496303 No abstract available.
PFS24 as a prognostic milestone in patients with newly diagnosed primary CNS lymphoma.
Zeremski V, Haage TR, Witte HM, Adolph L, Beer SA, Behre G, Jacobs B, Kahl C, Lalayanni C, Panse J, Papageorgiou S, Siakantaris MP, Schneider J, Schnetzke U, Schulz A, Vassilakopoulos TP, Walter J, Mougiakakos D. Zeremski V, et al. Among authors: vassilakopoulos tp. J Hematol Oncol. 2025 Apr 24;18(1):48. doi: 10.1186/s13045-025-01700-7. J Hematol Oncol. 2025. PMID: 40275355 Free PMC article.
Genetic Characterization of Primary Mediastinal B-Cell Lymphoma: Pathogenesis and Patient Outcomes.
Noerenberg D, Briest F, Hennch C, Yoshida K, Hablesreiter R, Takeuchi Y, Ueno H, Staiger AM, Ziepert M, Asmar F, Locher BN, Toth E, Weber T, Amini RM, Klapper W, Bouzani M, Poeschel V, Rosenwald A, Held G, Campo E, Ishaque N, Stamatopoulos K, Kanellis G, Anagnostopoulos I, Bullinger L, Goldschmidt N, Zinzani PL, Bödör C, Rosenquist R, Vassilakopoulos TP, Ott G, Ogawa S, Damm F. Noerenberg D, et al. Among authors: vassilakopoulos tp. J Clin Oncol. 2024 Feb 1;42(4):452-466. doi: 10.1200/JCO.23.01053. Epub 2023 Dec 6. J Clin Oncol. 2024. PMID: 38055913
Prognostic factors in Hodgkin lymphoma.
Bröckelmann PJ, Angelopoulou MK, Vassilakopoulos TP. Bröckelmann PJ, et al. Among authors: vassilakopoulos tp. Semin Hematol. 2016 Jul;53(3):155-64. doi: 10.1053/j.seminhematol.2016.05.003. Epub 2016 May 12. Semin Hematol. 2016. PMID: 27496306 Review.
Treatment of splenic marginal zone lymphoma.
Kalpadakis C, Pangalis GA, Angelopoulou MK, Vassilakopoulos TP. Kalpadakis C, et al. Among authors: vassilakopoulos tp. Best Pract Res Clin Haematol. 2017 Mar-Jun;30(1-2):139-148. doi: 10.1016/j.beha.2016.07.004. Epub 2016 Nov 4. Best Pract Res Clin Haematol. 2017. PMID: 28288709 Review.
Nodal marginal zone lymphoma.
Angelopoulou MK, Kalpadakis C, Pangalis GA, Kyrtsonis MC, Vassilakopoulos TP. Angelopoulou MK, et al. Among authors: vassilakopoulos tp. Leuk Lymphoma. 2014 Jun;55(6):1240-50. doi: 10.3109/10428194.2013.840888. Epub 2013 Nov 12. Leuk Lymphoma. 2014. PMID: 24004184 Review.
212 results